Influenza Diagnostics Market by Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user (Hospital, Clinic, Reference lab, POC, Home Care Agency) - Global Forecast to 2021

[127 Pages Report] The influenza diagnostics market is expected to reach USD 767.4 Million by 2021 from USD 508.0 Million in 2016, at a CAGR of 8.6% from 2016 to 2021. The increasing prevalence of influenza, growth in research funding for influenza diagnostics, and rising demand for faster diagnosis and control of influenza are the major factors that are expected to drive the market growth in the coming years. However, variability in sensitivity and specificity among influenza diagnostic tests, presence of a complex regulatory framework for the approval of new diagnostic tests, and rising healthcare costs are expected to restrain the growth of the market to a certain extent in the coming years.

This report segments the market on the basis of test type, end user, and region. On the basis of test type, the market is segmented into traditional and molecular diagnostic tests. The traditional diagnostic tests segment is expected to account for the largest share of the global influenza diagnostics market in 2016.

On the basis of end user, the market is segmented into hospitals/clinical laboratories, reference laboratories, and other end users (point-of-care testing, home health agencies, and nursing homes).

On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the influenza diagnostics market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

Geographic analysis reveals that Europe is expected to account for the largest share of the market in 2016. This can be attributed to the rapidly increasing prevalence of influenza in Europe and rising spending on R&D by top players in this region. Similarly, Asia-Pacific is estimated to grow at the highest CAGR during the forecast period. Increasing prevalence of influenza, increased healthcare expenditure, growing demand for advanced diagnostic technologies, and government initiatives are expected to drive the influenza diagnostics market in this region.

The major players in the influenza diagnostics market are Thermo Fisher Scientific (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Quidel Corporation (U.S.), Becton, Dickinson and Company (U.S.), DiaSorin (Italy), SA Scientific (U.S.), and Luminex Corporation (U.S.).

Target Audience for Influenza Diagnostics Market Research Report:

• Physicians
• Academic Institutes
• Diagnostic Solution Providers
• Research Institutes
• Reference Laboratories
• Diagnostic Suppliers
• Home Health Agencies
• Market Research and Consulting Firms

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Influenza Diagnostics Market Research Report

This research report categorizes the influenza diagnostics market into the following segments and subsegments:

Influenza Diagnostics Market by Test Type

• Traditional Diagnostic Tests
• Viral Culture
• Rapid Influenza Detection Tests (RIDT)
• Direct Fluorescent Antibody (DFA) Tests
• Serological Assays
• Molecular Diagnostic Tests
• RT-PCR
• Nucleic Acid Sequence-based Amplification (NASBA) Tests
• Loop-mediated Isothermal Amplification-based Assays (LAMP)
• Simple Amplification-based Assays (SAMBA)
• Other Tests (Microarray-based Approaches and Nucleic Acid Sequencing Approaches)

Influenza Diagnostics Market by End User

• Hospitals & Clinics
• Reference Laboratories
• Other End Users

Influenza Diagnostics Market by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • RoE
• Asia-Pacific
• Rest of the World

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

• Further breakdown of the APAC influenza diagnostics market into India, China, Australia, and Rest of APAC

Company Information

• Detailed analysis and profiling of additional market players (Up to 5)

Table of Contents

1 Introduction (Page No. - 14)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
           1.2.2 Years Considered in the Report
    1.3 Currency
    1.4 Limitations
    1.5 Stakeholders

2 Research Methodology (Page No. - 17)
    2.1 Market Size Estimation
    2.2 Market Ranking Analysis
    2.3 Market Breakdown and Data Triangulation
           2.3.1 Key Data From Secondary Sources
           2.3.2 Key Data From Primary Sources
           2.3.3 Assumptions for the Study

3 Executive Summary (Page No. - 24)
    3.1 Introduction
    3.2 Conclusion

4 Premium Insights (Page No. - 29)
    4.1 Influenza Diagnostics: Market Overview
    4.2 Geographic Analysis: Traditional Diagnostic Tests Market, By Type (2016)
    4.3 Molecular Diagnostic Tests Market Size, By Type, 2016 vs 2021 (USD Million)
    4.4 Life Cycle Analysis, By Region (2016)

5 Market Overview (Page No. - 32)
    5.1 Introduction
    5.2 Drivers
           5.2.1 Increasing Prevalence of Influenza
           5.2.2 Growth in Research Funding for Influenza Diagnostics
           5.2.3 Rising Demand for Faster Diagnosis and Control of Influenza
    5.3 Restraints
           5.3.1 Variability in Sensitivity and Specificity Among Influenza Diagnostic Tests
           5.3.2 Stringent Regulatory Framework
           5.3.3 Rising Healthcare Costs Limiting the Usage of Novel Influenza Diagnostic Techniques
    5.4 Opportunities
           5.4.1 Advancements in Genomic and Proteomic Technologies
           5.4.2 Significant Growth Prospects in Developing Countries
    5.5 Challenge
           5.5.1 Dearth of Skilled Personnel to Handle Advanced Influenza Diagnostic Tools
    5.6 Regulatory Framework
           5.6.1 North America
           5.6.2 Europe
           5.6.3 Asia-Pacific
                    5.6.3.1 India
                    5.6.3.2 China
                    5.6.3.3 Australia

6 Influenza Diagnostics Market, By Test Type (Page No. - 39)
    6.1 Introduction
    6.2 Traditional Diagnostic Tests
           6.2.1 Rapid Influenza Detection Tests (RIDT)
           6.2.2 Viral Culture
           6.2.3 Direct Fluorescent Antibody (DFA) Tests
           6.2.4 Serological Assays
    6.3 Molecular Diagnostic Tests
           6.3.1 RT-PCR
           6.3.2 Nucleic Acid Sequence-Based Amplification (NASBA) Tests
           6.3.3 Loop-Mediated Isothermal Amplification-Based Assays (LAMP)
           6.3.4 Simple Amplification-Based Assays (SAMBA)
           6.3.5 Other Molecular Diagnostic Tests

7 Influenza Diagnostics Market, By End User (Page No. - 60)
    7.1 Introduction
    7.2 Hospitals/Clinical Laboratories
    7.3 Reference Laboratories
    7.4 Other End Users

8 Influenza Diagnostics Market, By Region (Page No. - 66)
    8.1 Introduction
    8.2 Pest Analysis
           8.2.1 Political Factors
           8.2.2 Economic Factors
           8.2.3 Sociocultural Factors
           8.2.4 Technological Factors
    8.3 Europe
           8.3.1 Germany
           8.3.2 U.K.
           8.3.3 Rest of Europe
    8.4 North America
           8.4.1 U.S.
           8.4.2 Canada
    8.5 Asia-Pacific
    8.6 Rest of the World (RoW)

9 Competitive Landscape (Page No. - 92)
    9.1 Overview
    9.2 Leading Players in the Market
    9.3 Competitive Situation and Trends
           9.3.1 Product Launches and Approvals
           9.3.2 Acquisitions
           9.3.3 Expansions
           9.3.4 Collaborations and Agreements

10 Company Profiles (Page No. - 98)
     10.1 Introduction
(Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*
     10.2 F. Hoffmann-La Roche AG
     10.3 Becton, Dickinson and Company
     10.4 Thermo Fisher Scientific Inc.
     10.5 Alere Inc.
     10.6 Diasorin S.P.A.
     10.7 Quidel Corporation
     10.8 Meridian Bioscience, Inc.
     10.9 Analytik Jena AG (A Subsidiary of Endress+Hauser AG)
     10.10 Luminex Corporation
     10.11 SA Scientific, Ltd.

*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured In Case Of Unlisted Companies.

11 Appendix (Page No. - 117)
     11.1 Insights of Industry Experts
     11.2 Discussion Guide
     11.3 Other Developments
     11.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
     11.5 Introducing RT: Real-Time Market Intelligence
     11.6 Available Customizations
     11.7 Related Reports
     11.8 Author Details

List of Tables (91 Tables)

Table 1 Global Market Summary
Table 2 Market Size, By Test Type, 2014–2021 (USD Million)
Table 3 Global Market Size for Traditional Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 4 Market Size for Traditional Diagnostic Tests, By Region, 2014–2021 (USD Million)
Table 5 North America: Market Size for Traditional Diagnostic Tests, By Country, 2014–2021 (USD Million)
Table 6 Europe: Market Size for Traditional Diagnostic Tests, By Country, 2014–2021 (USD Million)
Table 7 Global Market Size for RIDT, By Region, 2014–2021 (USD Million)
Table 8 North America: Market Size for RIDT, By Country, 2014–2021 (USD Million)
Table 9 Europe: Market Size for RIDT, By Country, 2014–2021 (USD Million)
Table 10 Global Market Size for Viral Culture, By Region, 2014–2021 (USD Million)
Table 11 North America: Market Size for Viral Culture, By Country, 2014–2021 (USD Million)
Table 12 Europe: Influenza Diagnostics Market Size for Viral Culture, By Country, 2014–2021 (USD Million)
Table 13 Market Size for DFA Tests, By Region, 2014–2021 (USD Million)
Table 14 North America: Market Size for DFA Tests, By Country, 2014–2021 (USD Million)
Table 15 Europe: Market Size for DFA Tests, By Country, 2014–2021 (USD Million)
Table 16 Global Market Size for Serological Assays, By Region, 2014–2021 (USD Million)
Table 17 North America: Market Size for Serological Assays, By Country, 2014–2021 (USD Million)
Table 18 Europe: Market Size for Serological Assays, By Country, 2014–2021 (USD Million)
Table 19 Market Size for Molecular Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 20 Global Market Size for Molecular Tests, By Region, 2014–2021 (USD Million)
Table 21 North America: Market Size for Molecular Tests, By Country, 2014–2021 (USD Million)
Table 22 Europe: Global Market Size for Molecular Tests, By Country, 2014–2021 (USD Million)
Table 23 Market Size for RT-PCR, By Region, 2014–2021 (USD Million)
Table 24 North America: Market Size for RT-PCR, By Country, 2014–2021 (USD Million)
Table 25 Europe: Market Size for RT-PCR, By Country, 2014–2021 (USD Million)
Table 26 Global Market Size for NASBA, By Region, 2014–2021 (USD Million)
Table 27 North America: Market Size for NASBA, By Country, 2014–2021 (USD Million)
Table 28 Europe: Market Size for NASBA, By Country, 2014–2021 (USD Million)
Table 29 Market Size for LAMP, By Region, 2014–2021 (USD Million)
Table 30 North America: Market Size for LAMP, By Country, 2014–2021 (USD Million)
Table 31 Europe: Market Size for LAMP, By Country, 2014–2021 (USD Million)
Table 32 Global Market Size for SAMBA, By Region, 2014–2021 (USD Million)
Table 33 North America: Market Size for SAMBA, By Country, 2014–2021 (USD Million)
Table 34 Europe: Market Size for SAMBA, By Country, 2014–2021 (USD Million)
Table 35 Market Size for Other Molecular Diagnostic Tests, By Region, 2014–2021 (USD Million)
Table 36 North America: Market Size for Other Molecular Diagnostic Tests, By Country, 2014–2021 (USD Million)
Table 37 Europe: Market Size for Other Molecular Diagnostic Tests, By Country, 2014–2021 (USD Million)
Table 38 Market Size, By End User, 2014–2021 (USD Million)
Table 39 Market Size for Hospitals/Clinical Laboratories, By Region, 2014–2021 (USD Million)
Table 40 North America: Market Size for Hospitals/Clinical Laboratories, By Country, 2014–2021 (USD Million)
Table 41 Europe: Market Size for Hospitals/Clinical Laboratories, By Country, 2014–2021 (USD Million)
Table 42 Market Size for Reference Laboratories, By Region, 2014–2021 (USD Million)
Table 43 North America: Influenza Diagnostics Market Size for Reference Laboratories, By Country, 2014–2021 (USD Million)
Table 44 Europe: Market Size for Reference Laboratories, By Country, 2014–2021 (USD Million)
Table 45 Market Size for Other End Users, By Region, 2014–2021 (USD Million)
Table 46 North America: Market Size for Other End Users, By Country, 2014–2021 (USD Million)
Table 47 Europe: Market Size for Other End Users, By Country, 2014–2021 (USD Million)
Table 48 Global Market Size, By Region, 2014–2021 (USD Million)
Table 49 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 50 Europe: Market Size, By Country, 2014–2021 (USD Million)
Table 51 Europe: Market Size, By Test Type, 2014–2021 (USD Million)
Table 52 Europe: Market Size for Traditional Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 53 Europe: Market Size for Molecular Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 54 Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 55 Germany: Market Size, By Test Type, 2014–2021 (USD Million)
Table 56 Germany: Market Size for Traditional Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 57 Germany: Global Market Size for Molecular Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 58 Germany: Market Size, By End User, 2014–2021 (USD Million)
Table 59 U.K.: Market Size, By Test Type, 2014–2021 (USD Million)
Table 60 U.K.: Market Size for Traditional Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 61 U.K.: Market Size for Molecular Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 62 U.K.: Market Size, By End User, 2014–2021 (USD Million)
Table 63 RoE: Market Size, By Test Type, 2014–2021 (USD Billion)
Table 64 RoE: Market Size for Traditional Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 65 RoE: Market Size for Molecular Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 66 RoE: Market Size, By End User, 2014–2021 (USD Million)
Table 67 North America: Market Size, By Test Type, 2014–2021 (USD Million)
Table 68 North America: Market Size for Traditional Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 69 North America: Market Size for Molecular Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 70 North America: Influenza Diagnostics Market Size, By End User, 2014–2021 (USD Million)
Table 71 U.S.: Market Size, By Test Type, 2014–2021 (USD Million)
Table 72 U.S.: Market Size for Traditional Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 73 U.S.: Global Market Size for Molecular Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 74 U.S.: Market Size, By End User, 2014–2021 (USD Million)
Table 75 Canada: Market Size, By Test Type, 2014–2021 (USD Million)
Table 76 Canada: Market Size for Traditional Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 77 Canada: Market Size for Molecular Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 78 Canada: Influenza Diagnostics Market Size, By End User, 2014–2021 (USD Million)
Table 79 APAC: Market Size, By Test Type, 2014–2021 (USD Billion)
Table 80 APAC: Market Size for Traditional Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 81 APAC: Global Market Size for Molecular Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 82 APAC: Market Size, By End User, 2014–2021 (USD Million)
Table 83 RoW: Market Size, By Test Type, 2014–2021 (USD Million)
Table 84 RoW: Market Size for Traditional Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 85 RoW: Global Market Size for Molecular Diagnostic Tests, By Type, 2014–2021 (USD Million)
Table 86 RoW: Global Market Size, By End User, 2014–2021 (USD Million)
Table 87 Rank of Companies in the Influenza Diagnostics Market, 2015
Table 88 Product Launches and Approvals, 2014–2016
Table 89 Acquisitions, 2014–2016
Table 90 Expansions, 2014–2016
Table 91 Collaborations and Agreements, 2014–2016

List of Figures (33 Figures)

Figure 1 Research Design
Figure 2 Market Size Estimation Methodology: Bottom-Up Approach
Figure 3 Market Size Estimation Methodology: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Global Market Size, By Test Type, 2016 vs 2021 (USD Million)
Figure 7 Traditional Diagnostic Tests Market Size, By Type, 2016 vs 2021 (USD Million)
Figure 8 Molecular Diagnostic Tests Market Size, By Type, 2016 vs 2021 (USD Million)
Figure 9 Global Market Size, By End User, 2016 vs 2021 (USD Million)
Figure 10 Geographical Snapshot of the Influenza Diagnostics Market
Figure 11 Rising Prevalence of Influenza Across the Globe to Drive the Global Market
Figure 12 Rapid Influenza Detection Tests to Command the Largest Market Share in 2016
Figure 13 RT-PCR to Register the Highest Growth in the Forecast Period
Figure 14 Asia-Pacific Presents Lucrative Growth Opportunities for Players in the Global Market
Figure 15 Influenza Diagnostics Market Drivers, Restraints, Opportunities, and Challenges
Figure 16 RIDT to Dominate the Traditional Diagnostic Tests Market in 2016
Figure 17 RT-PCR to Dominate the Molecular Diagnostic Tests Market in 2016
Figure 18 Hospitals/Clinical Laboratories to Dominate the End-User Market in 2016
Figure 19 Geographic Snapshot: Asia-Pacific to Be the Fastest-Growing Region During the Forecast Period
Figure 20 Europe: Market Snapshot
Figure 21 North America: Market Snapshot
Figure 22 Companies Majorly Pursued the Strategy of Product Launches and Approvals Between 2014 and 2016
Figure 23 Battle for Market Share: Product Launches and Approvals Was the Key Strategy Adopted By Market Players in Influenza Diagnostics Market Between 2014 and 2016
Figure 24 Geographic Revenue Mix of the Top 5 Market Players (2015)
Figure 25 F. Hoffmann-La Roche AG: Company Snapshot (2015)
Figure 26 Becton, Dickinson and Company: Company Snapshot (2016)
Figure 27 Thermo Fisher Scientific Inc.: Company Snapshot (2015)
Figure 28 Alere Inc.: Company Snapshot (2015)
Figure 29 Diasorin S.P.A.: Company Snapshot (2015)
Figure 30 Quidel Corporation: Company Snapshot (2015)
Figure 31 Meridian Bioscience, Inc.: Company Snapshot (2015)
Figure 32 Analytik Jena AG: Company Snapshot (2014)
Figure 33 Luminex Corporation: Company Snapshot (2015)

The influenza diagnostics market is expected to reach USD 767.4 Million by 2021 from USD 508.0 Million in 2016, at a CAGR of 8.6% from 2016 to 2021. The increasing prevalence of influenza, growth in research funding for influenza diagnostics, and rising demand for faster diagnosis and control of influenza are the major factors that are expected to drive the growth of this market in the coming years. However, variability in sensitivity and specificity among influenza diagnostic tests, presence of a complex regulatory framework for the approval of new diagnostic tests, and rising healthcare costs are expected to restrain the growth of this market to a certain extent in the coming years.

This report segments the global market on the basis of test type, end user, and region. On the basis of test type, the market is segmented into traditional and molecular diagnostic tests. The traditional diagnostic tests segment is further categorized into rapid influenza detection tests (RIDT), viral culture, direct fluorescent antibody (DFA) tests, and serological assays. In 2016, the RIDT segment is expected to account for the largest share of the traditional diagnostic tests market owing to factors such as its user-friendliness, rapid generation of results, and easy interpretability. The molecular diagnostic tests segment is further categorized into RT-PCR, nucleic acid sequence-based amplification (NASBA) tests, loop-mediated isothermal amplification-based assays (LAMP), and simple amplification-based assays (SAMBA). In 2016, the RT-PCR segment is expected to hold the largest share of the molecular diagnostic tests market due to its ability to detect and distinguish between influenza A and B viruses with high specificity.

On the basis of end user, the market is segmented into hospitals/clinical laboratories, reference laboratories, and other end users (point-of-care testing, home health agencies, and nursing homes). The hospitals/clinical laboratories segment is expected to dominate the market in 2016. The large share of this segment can be attributed to the fact that most influenza disease diagnostic tests are carried out in hospitals and clinical laboratories, as these tests are highly complex in nature and require the use of specialized instruments.

On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Geographic analysis reveals that Europe is expected to account for the largest share of the global market in 2016. Growth in this market can be attributed to the rapidly increasing prevalence of influenza and rise in aging population in this region. Similarly, Asia-Pacific is estimated to grow at the highest CAGR during the forecast period. The main factors driving market growth are the increasing prevalence of influenza, increased healthcare expenditure, growing demand for advanced diagnostic technologies, and government initiatives.

The major players in influenza diagnostics market include Alere Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Becton, Dickinson and Company (U.S.), QIAGEN (Netherlands), Roche Diagnostics (Switzerland), and Abbott (U.S.).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst